West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Analyst Upgrades and Downgrades
Separately, StockNews.com cut West Pharmaceutical Services from a "buy" rating to a "hold" rating in a report on Thursday, April 28th.
West Pharmaceutical Services Stock Down 0.3 %
Shares of NYSE:WST opened at $337.75 on Friday. The firm has a market cap of $25.01 billion, a price-to-earnings ratio of 37.49, a PEG ratio of 1.33 and a beta of 1.15. The company has a quick ratio of 2.41, a current ratio of 3.13 and a debt-to-equity ratio of 0.09. West Pharmaceutical Services has a 52-week low of $275.89 and a 52-week high of $475.35. The business's 50 day moving average is $310.36 and its two-hundred day moving average is $346.54.
West Pharmaceutical Services (NYSE:WST - Get Rating) last announced its earnings results on Thursday, July 28th. The medical instruments supplier reported $2.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.19 by $0.28. The company had revenue of $771.30 million for the quarter, compared to analyst estimates of $754.25 million. West Pharmaceutical Services had a return on equity of 29.08% and a net margin of 23.41%. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.46 earnings per share. Research analysts predict that West Pharmaceutical Services will post 9.1 EPS for the current year.
Insider Buying and Selling at West Pharmaceutical Services
In other West Pharmaceutical Services news, insider Silji Abraham sold 5,374 shares of the business's stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $343.93, for a total value of $1,848,279.82. Following the sale, the insider now owns 3,201 shares of the company's stock, valued at $1,100,919.93. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by corporate insiders.